前立腺肥大症治療薬市場：治療クラス、治療法、エンドユーザー別-2025-2030年の世界予測

前立腺肥大症治療薬市場は、2023年に85億8,000万米ドルと評価され、2024年には91億7,000万米ドルに達すると予測され、CAGR 6.97％で成長し、2030年には137億6,000万米ドルに達すると予測されています。

前立腺肥大症（BPH）治療には、前立腺肥大症の症状緩和を目的としたさまざまな医療プロトコルが含まれます。ヘルスケア市場では、BPHは主に50歳以上の男性に影響を与え、排尿障害を引き起こす前立腺の非がん性肥大と定義されています。BPH治療の必要性は、重篤な尿閉、腎障害、尿路感染症の再発の可能性から生じ、早期管理が重要です。治療は、α遮断薬や5α還元酵素阻害薬のような薬物療法から、外科的介入、経尿道的前立腺切除術（TURP）やレーザー治療のような低侵襲手術まで多岐にわたる。最終用途は主に病院、診療所、外来手術センターです。

市場成長の原動力は、男性人口の高齢化、男性の健康に対する意識の高まり、低侵襲手術の進歩、併用療法の急増です。個別化医療と新規ドラッグデリバリーシステムの開発に焦点を当てた最近の研究は、潜在的なビジネスチャンスを秘めています。さらに、新興国におけるヘルスケア・アクセスの拡大は、未開拓の道を示しています。しかし、高額な治療費、厳しい規制要件、特定の治療における性機能障害などの潜在的な副作用などの要因が課題となっています。

戦略的な提言としては、副作用を最小限に抑えた革新的な治療のための研究開発への投資や、医薬品と医療機器の統合の強化などが挙げられます。強固な規制コンプライアンスを維持し、市場浸透を高めるためにヘルスケアプロバイダーとのパートナーシップを促進することも有利に働く。市場は、患者フォローアップのための遠隔医療相談や症状モニタリングのためのモバイルヘルスアプリなど、デジタルヘルスアプリケーションの機が熟しており、潜在的な革新分野を提供します。最終的には、顧客の嗜好を理解し、疾患に関する認識と教育を促進することが、市場の成功には不可欠です。全体として、前立腺肥大症治療市場は、技術革新、人口動向、戦略的パートナーシップに左右される中程度から堅調な成長見通しを特徴とします。

市場力学：急速に進化する前立腺肥大症治療薬市場の主要市場インサイトを公開

前立腺肥大症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 前立腺肥大症患者の増加
  • 手術や薬物・治療法の承認に対する有利な払い戻し
  • ヘルスケアインフラ改善への政府投資
• 市場抑制要因
  • 前立腺肥大症治療に関連する副作用
• 市場機会
  • 前立腺肥大症に対する低侵襲治療の登場
  • 前立腺肥大症に関する継続的な研究開発
• 市場の課題
  • 治療効果の不足

ポーターの5つの力：前立腺肥大症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：前立腺肥大症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、前立腺肥大症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析前立腺肥大症治療薬市場における競合情勢の把握

前立腺肥大症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス前立腺肥大症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、前立腺肥大症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨前立腺肥大症治療薬市場における成功への道筋を描く

前立腺肥大症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 前立腺肥大症の場合の成長
    • 手術や薬剤、治療の承認に対する有利な償還
    • ヘルスケアインフラの改善に対する政府の投資
  • 抑制要因
    • BPH治療に関連する副作用
  • 機会
    • 前立腺肥大症に対する低侵襲治療の登場
    • 前立腺肥大症に関する継続的な研究開発
  • 課題
    • 治療の有効性の欠如
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 前立腺肥大症治療薬市場治療クラス別

• 5-アルファ還元酵素阻害剤
• アルファ遮断薬
• ホスホジエステラーゼ5阻害剤

第7章 前立腺肥大症治療薬市場セラピー

• 併用薬物療法
• モノ薬物療法

第8章 前立腺肥大症治療薬市場：エンドユーザー別

• 外来手術センター
• 病院
• 専門クリニック

第9章 南北アメリカの前立腺肥大症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の前立腺肥大症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの前立腺肥大症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Asahi Kasei Corporation
• Astellas Pharma Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Eli Lilly and Company
• Endo International PLC
• GlaxoSmithKline plc
• Merck KGaA
• Mylan N.V.
• Pfizer, Inc.
• Sanofi S.A.
• Teleflex Incorporated
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA-BLOCKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COMBINATION DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MONO DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 29. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 30. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 46. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 47. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 49. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 50. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 101. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 102. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 113. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 114. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 116. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 117. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Benign Prostatic Hyperplasia Treatment Market was valued at USD 8.58 billion in 2023, expected to reach USD 9.17 billion in 2024, and is projected to grow at a CAGR of 6.97%, to USD 13.76 billion by 2030.

Benign Prostatic Hyperplasia (BPH) treatment encompasses a variety of medical protocols aimed at alleviating the symptoms of an enlarged prostate. In the healthcare market, BPH is defined as non-cancerous enlargement of the prostate gland affecting primarily men over 50, causing urinary issues. The necessity of BPH treatment arises from the potential for severe urinary retention, kidney damage, and recurrent urinary tract infections, making early management critical. Treatments range from medications like alpha-blockers and 5-alpha-reductase inhibitors to surgical interventions and minimally invasive procedures such as transurethral resection of the prostate (TURP) and laser therapies. The application scope extends to pharmaceuticals, medical devices, and healthcare services sectors, with end-use primarily in hospitals, clinics, and ambulatory surgical centers.

Market growth is driven by the aging male population, increasing awareness about men's health, advancements in minimally invasive procedures, and the burgeoning adoption of combination therapies. Recent research focusing on personalized medicine and the development of novel drug delivery systems holds potential opportunities. Furthermore, expanding healthcare access in emerging economies presents untapped avenues. However, factors such as high treatment costs, strict regulatory requirements, and potential side effects like sexual dysfunction in certain treatments pose challenges.

Strategic recommendations include investing in R&D for innovative treatments with minimal side effects and enhancing drug-device integration. Maintaining robust regulatory compliance and fostering partnerships with healthcare providers for improved market penetration can be advantageous. The market is ripe for digital health applications such as telemedicine consultations for patient follow-up and mobile health apps for symptom monitoring, offering potential areas of innovation. Ultimately, understanding customer preferences and promoting awareness and education about the condition is vital for market success. Overall, the BPH treatment market is characterized by moderate to robust growth prospects, hinged on technological innovation, demographic trends, and strategic partnerships.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Benign Prostatic Hyperplasia Treatment Market

The Benign Prostatic Hyperplasia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growth in cases of benign prostatic hyperplasia
  • Favorable reimbursement for surgeries and drug and treatemnt approvals
  • Government investments in improving healthcare infrastructure
• Market Restraints
  • Side-effects related to BPH treatment
• Market Opportunities
  • Emergence of minimally invasive treatments for benign prostatic hyperplasia
  • Ongoing research & development regarding benign prostatic hyperplasia
• Market Challenges
  • Lack of efficacy of treatments

Porter's Five Forces: A Strategic Tool for Navigating the Benign Prostatic Hyperplasia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Benign Prostatic Hyperplasia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Benign Prostatic Hyperplasia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Benign Prostatic Hyperplasia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Benign Prostatic Hyperplasia Treatment Market

A detailed market share analysis in the Benign Prostatic Hyperplasia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Benign Prostatic Hyperplasia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Benign Prostatic Hyperplasia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Benign Prostatic Hyperplasia Treatment Market

A strategic analysis of the Benign Prostatic Hyperplasia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Benign Prostatic Hyperplasia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Eli Lilly and Company, Endo International PLC, GlaxoSmithKline plc, Merck KGaA, Mylan N.V., Pfizer, Inc., Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Benign Prostatic Hyperplasia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapeutic Class, market is studied across 5-Alpha Reductase Inhibitor, Alpha-Blocker, and Phosphodiesterase-5 Inhibitor.
• Based on Therapy, market is studied across Combination Drug Therapy and Mono Drug Therapy.
• Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growth in cases of benign prostatic hyperplasia
    • 5.1.1.2. Favorable reimbursement for surgeries and drug and treatemnt approvals
    • 5.1.1.3. Government investments in improving healthcare infrastructure
  • 5.1.2. Restraints
    • 5.1.2.1. Side-effects related to BPH treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of minimally invasive treatments for benign prostatic hyperplasia
    • 5.1.3.2. Ongoing research & development regarding benign prostatic hyperplasia
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of efficacy of treatments
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Benign Prostatic Hyperplasia Treatment Market, by Therapeutic Class

• 6.1. Introduction
• 6.2. 5-Alpha Reductase Inhibitor
• 6.3. Alpha-Blocker
• 6.4. Phosphodiesterase-5 Inhibitor

7. Benign Prostatic Hyperplasia Treatment Market, by Therapy

• 7.1. Introduction
• 7.2. Combination Drug Therapy
• 7.3. Mono Drug Therapy

8. Benign Prostatic Hyperplasia Treatment Market, by End User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals
• 8.4. Specialty Clinics

9. Americas Benign Prostatic Hyperplasia Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Asahi Kasei Corporation
• 4. Astellas Pharma Inc.
• 5. Boehringer Ingelheim GmbH
• 6. Boston Scientific Corporation
• 7. Eli Lilly and Company
• 8. Endo International PLC
• 9. GlaxoSmithKline plc
• 10. Merck KGaA
• 11. Mylan N.V.
• 12. Pfizer, Inc.
• 13. Sanofi S.A.
• 14. Teleflex Incorporated
• 15. Teva Pharmaceutical Industries Ltd.